These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18506005)

  • 1. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
    Chan MY; Cohen MG; Dyke CK; Myles SK; Aberle LG; Lin M; Walder J; Steinhubl SR; Gilchrist IC; Kleiman NS; Vorchheimer DA; Chronos N; Melloni C; Alexander JH; Harrington RA; Tonkens RM; Becker RC; Rusconi CP
    Circulation; 2008 Jun; 117(22):2865-74. PubMed ID: 18506005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
    Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
    Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
    Cohen MG; Purdy DA; Rossi JS; Grinfeld LR; Myles SK; Aberle LH; Greenbaum AB; Fry E; Chan MY; Tonkens RM; Zelenkofske S; Alexander JH; Harrington RA; Rusconi CP; Becker RC
    Circulation; 2010 Aug; 122(6):614-22. PubMed ID: 20660806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
    Chan MY; Rusconi CP; Alexander JH; Tonkens RM; Harrington RA; Becker RC
    J Thromb Haemost; 2008 May; 6(5):789-96. PubMed ID: 18284597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.
    Povsic TJ; Cohen MG; Mehran R; Buller CE; Bode C; Cornel JH; Kasprzak JD; Montalescot G; Joseph D; Wargin WA; Rusconi CP; Zelenkofske SL; Becker RC; Alexander JH
    Am Heart J; 2011 Feb; 161(2):261-268.e1-2. PubMed ID: 21315207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.
    Povsic TJ; Wargin WA; Alexander JH; Krasnow J; Krolick M; Cohen MG; Mehran R; Buller CE; Bode C; Zelenkofske SL; Rusconi CP; Becker RC;
    Eur Heart J; 2011 Oct; 32(19):2412-9. PubMed ID: 21724623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
    Tanaka KA; Szlam F; Rusconi CP; Levy JH
    Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis.
    Becker RC; Chan MY
    Curr Opin Mol Ther; 2009 Dec; 11(6):707-15. PubMed ID: 20072947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.
    Szlam F; Luan D; Bolliger D; Szlam AD; Levy JH; Varner JD; Tanaka KA
    Thromb Res; 2010 May; 125(5):432-7. PubMed ID: 20004955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
    Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
    Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA aptamers as reversible antagonists of coagulation factor IXa.
    Rusconi CP; Scardino E; Layzer J; Pitoc GA; Ortel TL; Monroe D; Sullenger BA
    Nature; 2002 Sep; 419(6902):90-4. PubMed ID: 12214238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprotinin reduces the antiplatelet effect of clopidogrel.
    Lindvall G; Sartipy U; Bjessmo S; Svenarud P; Lindvall B; van der Linden J
    Interact Cardiovasc Thorac Surg; 2009 Aug; 9(2):178-81. PubMed ID: 19477870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.
    Becker RC; Oney S; Becker KC; Sullenger B
    Ann N Y Acad Sci; 2009 Sep; 1175():61-70. PubMed ID: 19796078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism.
    Eikelboom JW; Zelenkofske SL; Rusconi CP
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):382-7. PubMed ID: 20139356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
    Gilbert JC; DeFeo-Fraulini T; Hutabarat RM; Horvath CJ; Merlino PG; Marsh HN; Healy JM; Boufakhreddine S; Holohan TV; Schaub RG
    Circulation; 2007 Dec; 116(23):2678-86. PubMed ID: 18025536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.
    Povsic TJ; Cohen MG; Chan MY; Zelenkofske SL; Wargin WA; Harrington RA; Alexander JH; Rusconi CP; Becker RC
    J Thromb Thrombolysis; 2011 Jul; 32(1):21-31. PubMed ID: 21503856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial.
    Morrow DA; Murphy SA; McCabe CH; Mackman N; Wong HC; Antman EM
    Eur Heart J; 2005 Apr; 26(7):682-8. PubMed ID: 15684280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
    Erlinge D; Varenhorst C; Braun OO; James S; Winters KJ; Jakubowski JA; Brandt JT; Sugidachi A; Siegbahn A; Wallentin L
    J Am Coll Cardiol; 2008 Dec; 52(24):1968-77. PubMed ID: 19055987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.